Y-27632 dihydrochlaride,IC-0121685

Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor (ROCK-I Ki=220 nM; ROCK-II Ki=300 nM). Y-27632 dihydrochloride shows antiepileptic effects[1][2][3][4].

Western Blot Analysis[3]
Cell Line:Adipose tissue-derived stem cells (ADSCs)
Concentration: 20 ¦ÌM
Incubation Time:24 hours
Result: Resulted in the up-regulation of NSE, MAP-2 and nestin protein levels by 25.3, 3.1 and 2.5 fold, respectively, compared to control cells not treated by Y-27632.


Animal Model: Male Wistar rats injected with dimethylnitrosamine[1]
Dosage: 30 mg/kg
Administration: Oral gavage; 30 mg/kg; once daily; 4 weeks
Result: Decreased the occurrence of dimethylnitrosamine-induced hepatic fibrosis and reduced the collagen and hydroxyproline content and ¦Á-smooth muscle actin expression in the liver.

Animal Model: Male Swiss albino mice injected with PTZ (pentylenetetrazole) or induced by MES (maximal electroconvulsive shock)[2]
Dosage: 5-10 mg/kg
Administration: Oral gavage; 5-10 mg/kg; once
Result: Prolonged the onset time of myoclonic jerks when compared with those observed in the saline group (P<0.05).
Prolonged the onset time of clonic convulsions when compared with saline group (P<0.05).
Prevented the occurrence of tonic hindlimb extensions and death.

[1]. Tada S, et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. J Hepatol. 2001 Apr;34(4):529-36.  
[2]. Inan S, et al. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol. 2008 Sep;155(1):44-51.  
[3]. Xue ZW, et al. Rho-associated coiled kinase inhibitor Y-27632 promotes neuronal-like differentiation of adult human adipose tissue-derived stem cells. Chin Med J (Engl). 2012 Sep;125(18):3332-5.  
[4]. Ishizaki T, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.